System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish 23 citations

PubMed: 35721225 DOI: 10.1016/j.omtn.2022.06.006

Serum microRNAs targeting and genes distinguish asymptomatic from critical COVID-19 patients.

Mol Ther Nucleic Acids 29:76-87

Authors: Maria Calderon-Dominguez, Eva Trejo-Gutierrez, Almudena González-Rovira, Lucía Beltrán-Camacho, Marta Rojas-Torres, Sara Eslava-Alcón, Daniel Sanchez-Morillo, Juan Calderon-Dominguez, Mª Pilar Martinez-Nicolás, Estibaliz Gonzalez-Beitia, Mª Dolores Nieto-Martín, Teresa Trujillo-Soto, Manuel A Rodríguez-Iglesias, Juan A Moreno, Rafael Moreno-Luna, Mª Carmen Durán-Ruiz

Affiliations

  • Biomedicine, Biotechnology and Public Health Department, Cádiz University, 11002 Cádiz, Spain.
  • Biomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, Spain.
  • Biomedical Engineering and Telemedicine Research Group, Department of Automation Engineering, Electronics and Computer Architecture and Networks, Universidad de Cádiz, 11009 Cádiz, Spain.
  • Occupational Health Service, National Paraplegic Hospital, SESCAM, 45071 Toledo, Spain.
  • Internal Medicine Department, University Hospital Virgen del Rocío, Seville, Spain.
  • UGC Microbiología, University Hospital Puerta del Mar, Avda. Ana de Viya 21, 11009 Cádiz, Spain.
  • Biomedicine, Biotechnology and Public Health Department, Cádiz University, 11002 Cádiz, Spain. Biomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, Spain. UGC Microbiología, University Hospital Puerta del Mar, Avda. Ana de Viya 21, 11009 Cádiz, Spain.
  • Cell Biology, Physiology and Immunology Department, Agrifood Campus of International Excellence (ceiA3), University of Cordoba, 14014 Córdoba, Spain.
  • Maimonides Biomedical Research Institute of Cordoba (IMIBIC), UGC Nephrology, Hospital Universitario Reina Sofia, 14004 Cordoba, Spain.
  • Laboratory of Neuroinflammation, National Paraplegic Hospital, SESCAM, 45071 Toledo, Spain.

Abstract

Despite the extraordinary advances achieved to beat COVID-19 disease, many questions remain unsolved, including the mechanisms of action of SARS-CoV-2 and which factors determine why individuals respond so differently to the viral infection. Herein, we performed an analysis to identify host microRNA targeting , , and/or RAB14, all genes known to participate in viral entry and replication. Next, the levels of six microRNA candidates previously linked to viral and respiratory-related pathologies were measured in the serum of COVID-19-negative controls (n = 16), IgG-positive COVID-19 asymptomatic individuals (n = 16), and critical COVID-19 patients (n = 17). Four of the peripheral microRNAs analyzed (hsa-miR-32-5p, hsa-miR-98-3p, hsa-miR-423-3p, and hsa-miR-1246) were upregulated in COVID-19 critical patients compared with COVID-19-negative controls. Moreover, hsa-miR-32-5p and hsa-miR-1246 levels were also altered in critical versus asymptomatic individuals. Furthermore, these microRNA target genes were related to viral infection, inflammatory response, and coagulation-related processes. In conclusion, SARS-CoV-2 promotes the alteration of microRNAs targeting the expression of key proteins for viral entry and replication, and these changes are associated with disease severity. The microRNAs identified could be taken as potential biomarkers of COVID-19 progression as well as candidates for future therapeutic approaches against this disease.

MeSH

Infections, Genes, Serum, Micrornas, Covid-19, Sars-Cov-2

Cited by